Cabergoline versus bromocriptine in the treatment of hyperprolactinemia: A systematic review of randomized controlled trials and meta-analysis

Pituitary

Volumn 14, Issue 3, 2011, Pages 259-265

  Dos Santos Nunes, Vania ^a   El Dib, Regina ^a   Boguszewski, César Luiz ^b   Nogueira, Célia Regina ^a  

^a SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

^b FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

Author keywords

Dopaminergic agonists; Hyperprolactinemia; Meta analysis; Prolactinoma; Systematic review

Indexed keywords

BROMOCRIPTINE; CABERGOLINE;

ABDOMINAL PAIN; AMENORRHEA; ARTICLE; CONSTIPATION; DEPRESSION; DIZZINESS; DRUG INDUCED HEADACHE; DYSPEPSIA; FATIGUE; GALACTORRHEA; GASTRITIS; HOT FLUSH; HUMAN; HYPERPROLACTINEMIA; MASTALGIA; MENSTRUAL CYCLE; MENSTRUATION; META ANALYSIS; NAUSEA; ORTHOSTATIC HYPOTENSION; PREGNANCY; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PROLACTIN RELEASE; PROLACTINOMA; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SOMNOLENCE; SYSTEMATIC REVIEW; TUMOR VOLUME; VERTIGO; VOMITING;

BROMOCRIPTINE; DOPAMINE AGONISTS; ERGOLINES; HUMANS; HYPERPROLACTINEMIA; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 80053895923     PISSN: 1386341X     EISSN: 15737403     Source Type: Journal    
DOI: 10.1007/s11102-010-0290-z     Document Type: Article

References (27)

1. Brue T, Delemer B (2007) Diagnosis and management of hyperprolactinemia: expert consensus - French society of endocrinology. Ann Endocrinol (Paris) 68:58-64 (Pubitemid 46616591)
2. Casanueva FF et al (2006) Guidelines of the pituitary society for the diagnosis and management of prolactinomas. Clin Endocrinol (Oxf) 65:265-273 (Pubitemid 44079693)
3. Colao A, di Sarno A, Pivonello R, di Somma C, Lombardi G (2002) Dopamine receptor agonists for treating prolactinomas. Expert Opin Investig Drugs 11:787-800 (Pubitemid 34618811)
4. Colao A, Pivonello R, Di Somma C, Savastano S, Grasso LF, Lombardi G (2009) Medical therapy of pituitary adenomas: effects on tumor shrinkage. Rev Endocr Metab Disord 10: 111-123
5. Verhelst J, Abs R, Maiter D, van den Bruel A, Vandeweghe M, Velkeniers B, Mockel J, Lamberigts G, Petrossians P, Coremans P, Mahler C, Stevenaert A, Verlooy J, Raftopoulos C, Beckers A (1999) Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients. J Clin Endocrinol Metab 8:2518-2522
6. Colao A, Di Sarno A, Landi ML, Scavuzzo F, Cappabianca P, Pivonello R, Volpe R, Di Salle F, Cirillo S, Annunziato L, Lombardi G (2000) Macroprolactinoma shrinkage during cabergoline treatment is greater in naive patients than in patients pretreated with other dopamine agonists: a prospective study in 110 patients. J Clin Endocrinol Metab 85:2247-2252 (Pubitemid 32269250)
7. Alderson P, Green S, Higgins JPT (eds) (2004) Cochrane reviewers' handbook 4.2.2 the Cochrane library [updated December 2003]. Wiley, Chichester
8. Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327:557-560 (Pubitemid 37088507)
9. Webster J, Piscitelli G, Polli A, D'Alberton A, Falsetti L, Ferrari C, Fioretti P, Giordano G, L'Hermite M, Ciccarelli E et al (1992) Dose-dependent suppression of serum prolactin by cabergoline in hyperprolactinaemia: a placebo controlled, double blind, multi-centre study. European multicentre cabergoline dose-finding study group. Clin Endocrinol (Oxf) 37:534-541
10. Mattei AM, Ferrari C, Baroldi P, Cavioni V, Paracchi A, Galparoli C, Romano C, Spellecchia D, Gerevini G, Crosignani PG (1988) Prolactin-lowering effect of acute and once weekly repetitive oral administration of cabergoline at two dose levels in hyperprolactinemic patients. J Clin Endocrinol Metab 66: 193-198 (Pubitemid 18027751)
11. Bricaire C (2004) Interruption d'un traitement de longue durée par la cabergoline des hyperprolactinémies tumorales et non tumorales. La Revue du Praticien Gynécologie et Obstétrique 15:9-10 (Pubitemid 38917282)
12. Freda PU, Reyes CM, Nuruzzaman AT, Sundeen RE, Khandji AG, Post KD (2004) Cabergoline therapy of growth hormone & growth hormone/prolactin secreting pituitary tumors. Pituitary 7:21-30 (Pubitemid 39366128)
13. Di Somma C, Colao A, Di Sarno A, Klain M, Landi ML, Facciolli G, Pivonello R, Panza N, Salvatore M, Lombardi G (1998) Bone marker and bone density responses to dopamine agonist therapy in hyperprolactinemic males. J Clin Endocrinol Metab 83:807-813 (Pubitemid 28496451)
14. Bolko P, Jaskula M, Wasko R, Wolun M, Sowinski J (2003) The assessment of cabergoline efficacy and tolerability in patients with pituitary prolactinoma type. Pol Arch Med Wewn 109: 489-495
15. Ferrari C, Barbieri C, Caldara R, Mucci M, Codecasa F, Paracchi A, Romano C, Boghen M, Dubini A (1986) Long-lasting pro-lactin-lowering effect of cabergoline, a new dopamine agonist, in hyperprolactinemic patients. J Clin Endocrinol Metab 63: 941-945 (Pubitemid 16004299)
16. Di Sarno A, Landi ML, Cappabianca P, Di Salle F, Rossi FW, Pivonello R, Di Somma C, Faggiano A, Lombardi G, Colao A (2001) Resistance to cabergoline as compared with bromocriptine in hyperprolactinemia: prevalence, clinical definition, and therapeutic strategy. J Clin Endocrinol Metab 86:5256-5261 (Pubitemid 33070245)
17. De Rosa M, Colao A, Di Sarno A, Ferone D, Landi ML, Zarrilli S, Paesano L, Merola B, Lombardi G (1998) Cabergoline treatment rapidly improves gonadal function in hyperprolactinemic males: a comparison with bromocriptine. Eur J Endocrinol 138: 286-293 (Pubitemid 28154778)
18. Fideleff HL, Holland M, Chervin A, Gurucharri C, Sinai I (1997) Tratamiento de amenorreas hiperprolactinemicas con cabergolina. Medicina (B Aires) 57:657-661 (Pubitemid 28051832)
19. Sartorio A, Conti A, Ambrosi B, Muratori M, Morabito F, Faglia G (1990) Osteocalcin levels in patients with microprolactinoma before and during medical treatment. J Endocrinol Invest 13:419-422 (Pubitemid 20186189)
20. Vilar L et al (2008) Diagnosis and management of hyperprolac-tinemia: results of a Brazilian multicenter study with 1234 patients. J Endocrinol Invest 31:436-444 (Pubitemid 352005743)
21. Berinder K, Stackenas I, Akre O, Hirschberg AL, Hulting AL (2005) Hyperprolactinaemia in 271 women: up to three decades of clinical follow-up. Clin Endocrinol (Oxf) 63:450-455 (Pubitemid 41442340)
22. Cesar de Oliveira Naliato E, Dutra Violante AH, Caldas D, Lamounier Filho A, Rezende Loureiro C, Fontes R, Schrank Y, Gomes de Souza R, Vaisman M, Guerra E, Sebastian A, Colao A (2008) Quality of life in women with microprolactinoma treated with dopamine agonists. Pituitary 11:247-254
23. Al-Husaynei A, Mahmood I, Al-Jubori ZS (2008) Comparison of the effects of cabergoline and bromocriptine in women with hyperprolactinemic amenorrhea. Middle East Fertil Soc J 13: 33-38 (Pubitemid 352030215)
24. Sabuncu T, Arikan E, Tasan E, Hatemi H (2001) Comparison of the effects of cabergoline and bromocriptine on prolactin levels in hyperprolactinemic patients. Intern Med 40:857-861 (Pubitemid 32958781)
25. Pascal-Vigneron V, Weryha G, Bosc M, Leclere J (1995) Aménorrhée hyperprolactinémique: traitement par cabergoline versus bromocriptine. Résultats de l'étude nationale, multicentri-que, randomisée en double insu. La Presse Médicale 20:753-757
26. Webster J, Piscitelli G, Polli A, Ferrari CI, Ismail I, Scanlon MF (1994) A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline comparative study group. N Engl J Med 331:904-909 (Pubitemid 24299871)
27. Ferrari CI, Abs R, Bevan JS, Brabant G, Ciccarelli E, Motta T, Mucci M, Muratori M, Musatti L, Verbessem G, Scanlon MF (1997) Treatment of macroprolactinoma with cabergoline: a study of 85 patients. Clin Endocrinol (Oxf) 46:409-413 (Pubitemid 27242675)